I expect to see a slow and steady rise into the high 60's, before a re-rate following results mid-year that takes us back into the 80's and builds into closing the year above $1
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025